NEW YORK – New York City-based start-up Immunai aims to combine multiomic measurements with machine-learning analysis to develop immune profiles linked to disease.
The company, which has been operating in stealth mode since 2019, announced last week that it has raised $20 million in seed funding from investors including Viola Ventures and TLV Partners and has established clinical research collaborations with a number of medical centers as well as commercial partnerships with several biopharma companies focused on cancer immunotherapy.